CONTACT US

Appointment times can be worked flexibly around your needs and may be accommodated on evenings and weekends. You can also be seen at a private hospital close and convenient for you.

info@eyeproblems.uk.com

Clinic Locations

Manchester Royal Eye Hospital Private Patient Centre

Mr S Mahmood
Manchester Centre For Vision,Oxfordroad,Manchester;
Cheshire M13 9WL
Contact number:01614083456

Map

OPtegra Manchester Eye Hospital

Mr S Mahmood,
Optegra Manchester Eye Hospital,
One Didsbury Point,
2 The Avenue (Off the Boulevard),
Didsbury,
Manchester, Cheshire
M20 2EY
Contact number:01614083456

Map

The Wilmslow Hospital – 52 Alderley Road

Mr S Mahmood
52-54 Alderley Rd
Wilmslow
SK9 1NY

Map

EYE PROBLEM NEWS

Treat diabetic macular oedema with one eye injection in three years?

It may sound too good to be true but a new injectable steroid product is now on the market in the UK and comes with the claim that only one injection is required which can last three years. This product called Iluvien (drug name fluocinolone) is new slow release implant product licensed to treat diabetic macular oedema.

...

Eylea – finally a serious competitor Lucentis?

Eylea (also known as aflibercept and VEGF Trap Eye) has now been approved and licensed in Europe. It’s UK launch is planned for the begninning of december 2012. With great success so far on the American market the manufacturer (Regeneron) and distributor (Bayer) are hopeful that it will make an impact on treatment of wet AMD in the UK.

...

Cataract Surgery. Will the NHS or my insurance company pay?

Recently cataract surgery has been restricted by some primary care trusts in Manchester and Cheshire. The aim is to restrict surgery to patients who really need the operation but the thresholds, sometimes just based on vision chart measurements not quality of life have been set at a level which in some cases is a worse level of vision than would be necessary

...

Lucentis price cut in the UK

The biggest controversy in relation to treatment with lucentis has been the price. The need for repeated monthly review and repeat treatments soon cause the overall cost to build up. Understandably, the manufacturer needs to recoup the costs of such a ground breaking development and invest in future research.

...